Karthik Chetlapalli
About
Research
Publications
Featured Publications
Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis
Chetlapalli K, Ito S, Ng DQ, Sra MS, Wang D, Krumholz H, Krishnamurti L, Pandya A, Goshua G. Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis. Blood Journal 2026, blood.2025032290. DOI: 10.1182/blood.2025032290.Peer-Reviewed Original ResearchThis study investigates the cost-effectiveness of haploidentical stem cell transplantation, gene therapy, and standard care for sickle cell disease, showing transplantation offers the best value globally.Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria
Ito S, Chetlapalli K, Wang D, Potnis K, Richmond R, Krumholz H, Lee A, Cuker A, Goshua G. Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria. Blood 2024, 145: 127-140. PMID: 39374533, PMCID: PMC11738035, DOI: 10.1182/blood.2024025176.Peer-Reviewed Original ResearchStandard-of-careParoxysmal nocturnal hemoglobinuriaIncremental net monetary benefitNocturnal hemoglobinuriaComplement-mediated hemolytic anemiaTreating paroxysmal nocturnal hemoglobinuriaComplement C5 inhibitor eculizumabPhase 3 studyQuality-adjusted life expectancyRare blood disorderComprehensive cost-effectiveness analysisProbabilistic sensitivity analysesCost-saving thresholdsC5 inhibitor eculizumabNet monetary benefitPersistent anemiaIptacopanExtravascular hemolysisIntravenous infusionMonotherapyHemolytic anemiaAnemia resolutionC5 inhibitionFDA approvalPrimary outcome
2026
Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis
Chetlapalli K, Ito S, Ng D, Sra M, Wang D, Krumholz H, Krishnamurti L, Pandya A, Goshua G. Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis. Blood 2026 PMID: 42227898, DOI: 10.1182/blood.2025032290.Peer-Reviewed Original ResearchThis study investigates the cost-effectiveness of haploidentical stem cell transplantation, gene therapy, and standard care for sickle cell disease, showing transplantation offers the best value globally.
2024
Cost‐effectiveness of sutimlimab in cold agglutinin disease
Ito S, Wang D, Purcell A, Chetlapalli K, Lee A, Cuker A, Goshua G. Cost‐effectiveness of sutimlimab in cold agglutinin disease. American Journal Of Hematology 2024, 99: 1475-1484. PMID: 38733355, DOI: 10.1002/ajh.27358.Peer-Reviewed Original ResearchPrimary cold agglutinin diseaseCold agglutinin diseaseStandard-of-careIncremental cost-effectiveness ratioUS willingness-to-pay thresholdRare autoimmune hemolytic anemiaPhase 3 studyWillingness-to-pay thresholdsAutoimmune hemolytic anemiaTime-limited treatmentHuman monoclonal antibodyCold-reactive antibodiesBinding to red blood cellsFollow-up dataCost-effectiveness ratioComplement-mediated hemolysisDeterministic sensitivity analysisHealth resource utilizationProbabilistic sensitivity analysesTransfusion-DependentClinical remissionTransfusion supportImprove quality of lifeRed blood cellsHemolytic anemia
2020
Distinct Target-Specific Mechanisms Homeostatically Stabilize Transmission at Pre- and Post-synaptic Compartments
Goel P, Nishimura S, Chetlapalli K, Li X, Chen C, Dickman D. Distinct Target-Specific Mechanisms Homeostatically Stabilize Transmission at Pre- and Post-synaptic Compartments. Frontiers In Cellular Neuroscience 2020, 14: 196. PMID: 32676010, PMCID: PMC7333441, DOI: 10.3389/fncel.2020.00196.Peer-Reviewed Original ResearchPresynaptic homeostatic potentiationPost-synaptic compartmentsExpression mechanismHomeostatic controlStable synaptic strengthTarget-specific reductionPresynaptic neurotransmitter release probabilityPresynaptic neurotransmitter releaseNeurotransmitter release probabilityControl of neurotransmissionNeuromuscular junctionHomeostatic potentiationPostsynaptic glutamate receptorsHyper-innervationSynaptic strengthNeurotransmitter releaseTarget specificityPresynaptic adaptationsRelease probabilityDiverse targetsGlutamate receptorsFunctional characteristicsCompartmentGluRTarget